(IMVT) Immunovant - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.837m USD | Total Return: 113% in 12m
Avg Turnover: 55.0M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 34.4% YoY
Below Avwap Earnings
Tailwinds
Rs Leader, Confidence
Immunovant, Inc. is a clinical-stage biotechnology company focused on developing targeted monoclonal antibody therapies for autoimmune diseases. Its primary candidates, IMVT-1402 and batoclimab, are designed to inhibit the neonatal Fc receptor (FcRn), a mechanism intended to reduce pathogenic IgG antibodies across multiple indications including Graves disease, myasthenia gravis, and thyroid eye disease.
Operating within the immunology sector, the company utilizes a hub-and-spoke business model as a subsidiary of Roivant Sciences Ltd. This structure allows the firm to focus resources on specific therapeutic assets while leveraging centralized infrastructure for clinical development. The FcRn inhibitor market is characterized by high barriers to entry due to complex protein engineering requirements and intensive regulatory approval processes for chronic treatments.
Investors may find it useful to examine ValueRay for further data on the companys competitive positioning.
Founded in 2018 and headquartered in Durham, North Carolina, Immunovant continues to advance its pipeline through various stages of clinical trials. The companys success depends on the clinical efficacy of its subcutaneous delivery methods, which aim to provide a more patient-friendly alternative to traditional intravenous infusions.
- Clinical trial results for IMVT-1402 determine competitive advantage in FcRn inhibitor market
- Regulatory approval timelines for batoclimab dictate path to initial commercial revenue
- Potential acquisition by parent Roivant Sciences influences long-term equity valuation
- Expansion of clinical pipeline into multi-indication autoimmune treatments drives investor sentiment
- Competition from established pharmaceutical players impacts projected market share for lead assets
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA 5.96 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.43 > 3% & CFO -407.3m > Net Income -505.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (203.7m) vs 12m ago 34.40% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.02%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.88 (Total Current Assets 948.8m - Total Current Liabilities 104.4m) / Total Assets 957.0m |
| B: -1.82 (Retained Earnings -1.75b / Total Assets 957.0m) |
| C: -0.61 (EBIT TTM -527.6m / Avg Total Assets 866.6m) |
| D: 8.16 (Book Value of Equity 852.6m / Total Liabilities 104.4m) |
| Altman-Z'' = 4.33 = AA |
As of June 05, 2026, the stock is trading at USD 32.67 with a total of 1,342,107 shares traded.
Over the past week, the price has changed by -2.48%,
over one month by +17.31%,
over three months by +20.64% and
over the past year by +112.97%.
Immunovant has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IMVT.
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.7 | 36.9% |
P/B = 8.0188
Revenue TTM = 0.0 USD
EBIT TTM = -527.6m USD
EBITDA TTM = -527.2m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 72.0k USD (from shortTermDebt, last quarter)
Debt = 72.0k USD (from shortLongTermDebtTotal, last quarter) (leases 72.0k already included)
Net Debt = -902.0m USD (calculated: Debt 72.0k - CCE 902.1m)
Enterprise Value = 5.93b USD (6.84b + Debt 72.0k - CCE 902.1m)
Interest Coverage Ratio = unknown (Ebit TTM -527.6m / Interest Expense TTM 0.0)
EV/FCF = -14.57x (Enterprise Value 5.93b / FCF TTM -407.3m)
FCF Yield = -6.86% (FCF TTM -407.3m / Enterprise Value 5.93b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 409k) / Revenue TTM)
Tobins Q-Ratio = 6.20 (Enterprise Value 5.93b / Total Assets 957.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 72.0k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -416.8m (EBIT -527.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.09 (Total Current Assets 948.8m / Total Current Liabilities 104.4m)
Debt / Equity = 0.00 (Debt 72.0k / totalStockholderEquity, last quarter 852.6m)
Debt / EBITDA = 1.71 (negative EBITDA) (Net Debt -902.0m / EBITDA -527.2m)
Debt / FCF = 2.21 (negative FCF - burning cash) (Net Debt -902.0m / FCF TTM -407.3m)
Total Stockholder Equity = 741.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -58.34% (Net Income -505.6m / Total Assets 957.0m)
RoE = -68.16% (Net Income TTM -505.6m / Total Stockholder Equity 741.7m)
RoCE = -71.13% (EBIT -527.6m / Capital Employed (Equity 741.7m + L.T.Debt 0.0))
RoIC = -48.88% (negative operating profit) (NOPAT -416.8m / Invested Capital 852.7m)
WACC = 10.26% (E(6.84b)/V(6.84b) * Re(10.26%) + D(72.0k)/V(6.84b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 16.48%
[DCF] Fair Price = unknown (Cash Flow -407.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.41 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.48 | Chg30d=+47.91% | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.53 | Chg30d=+45.23% | Revisions=+20% | Analysts=1
EPS current Year (2027-03-31): EPS=-2.44 | Chg30d=+5.40% | Revisions=+50% | GrowthEPS=+0.9% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-2.44 | Chg30d=-2.29% | Revisions=+20% | GrowthEPS=+0.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +50%